Denovo Acquires Alzheimer's Disease Candidate from Lundbeck

Denovo Biopharma acquired global rights to an Alzheimer's disease candidate from H. Lundbeck, a Denmark neurological biopharma. The candidate, idalopirdine, is an oral antagonist of the serotonin (5-HT6) receptor that failed its Phase III trial in AD. Denovo, a Hangzhou-San Diego precision medicine company, will use its proprietary biomarker platform to search for pharmacogenomic predictors of idalopirdine's (DB109) efficacy in specific populations. Terms of the agreement were not disclosed. More details.... Share this with colleagues: // //